Filing Flows › Taysha Gene Therapies (TSHA) › Q1 2025
Taysha Gene Therapies (TSHA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Taysha Gene Therapies (TSHA) reported revenue of $2.3M for the first quarter 2025 (Q1 2025), -33% from a year earlier and +14% from the quarter before. Operating margin was -930.5%, net loss $21.5M (935.2% of revenue).
Taysha Gene Therapies, Q1 2025: revenue $2.3M (-32% year over year), operating margin -930.5%, net loss $21.5M, operating cash flow −$22.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | +14% | -33% |
| Operating profit | −$21.4M | — | — |
| Net earnings | −$21.5M | — | — |
| Operating cash flow | −$22.0M | — | — |
What changed
Revenue was $2.3M in Q1 2025, down 33% year over year and up 14% from the previous quarter.
Operating costs exceeded revenue by $21.4M, an operating margin of -930.5%. Total costs fell 14% while revenue fell 33%. The fastest-growing cost line was General & admin (+15%). The quarter ended with a net loss of $21.5M, wider than the previous quarter's $18.8M loss.
Operating cash flow was −$22.0M. Non-cash charges added back $283K of depreciation and $3.3M of share-based compensation. Working capital and other items used $4.1M. Capital expenditures of $378K exceeded it, leaving free cash flow of −$22.4M.
Questions
What was Taysha Gene Therapies' revenue in the first quarter 2025?
Taysha Gene Therapies (TSHA) reported revenue of $2.3M for the first quarter 2025 (Q1 2025), -33% from a year earlier and +14% from the quarter before.
Was Taysha Gene Therapies profitable in the first quarter 2025?
Operating loss was $21.4M (-930.5% of revenue) and net loss $21.5M.